Cancer cells with HR deficiency (e.g., with BRCA1/2 mutations) are uniquely sensitive to DNA crosslinking agents and PARP inhibitors, but some of these cells acquire de novo resistance to these drugs due to concomitant loss of the NHEJ pathway. This evidence concerns the gene BRCA1 and cancer.